Five Red Flags in Vendor Study Reports Before Submission
Five Red Flags in Vendor Study Reports Before Submission
What Sponsors Must Catch Early to Avoid Regulatory Delays
As biotech and pharmaceutical companies prepare for IND, CTA, NDA, or BLA submissions, one element consistently determines reviewer confidence: the quality and integrity of your study reports. Even well executed studies can create regulatory risk if the final reports contain inconsistencies, gaps, or signals that raise questions.
At Nikao Life Sciences, we review hundreds of nonclinical studies reports each year and the same preventable issues appear repeatedly.
Here are the five critical red flags to identify before your report becomes part of a regulatory submission.
- Inconsistent Data Between Text, Tables, and Raw Outputs
This is the most common and most concerning issue.
Examples include:
- Text summaries that don’t match table values
- Misaligned findings between draft and final versions
- Exposure values that contradict bioanalytical results
- Severity descriptions that change without explanation
Regulators assume if they find one inconsistency, more exist.
This can result in information requests, delayed timelines, or full re-review cycles.
What to do:
Conduct a line-by-line QC review ensuring text, tables, listings, and raw data all align.
- Missing Justification for Dose Selection or NOAEL
Regulators expect a clear scientific rationale behind:
- Dose selection (including MTD or tolerability data)
- Exposure margins
- NOAEL determination
- Changes from planned vs. actual doses
If these are missing, reviewers may question whether the study adequately supports clinical safety.
What to do:
Include a transparent, well-supported justification section based on PK, exposure, toxicity, and clinical relevance.
- Out-of-Scope Deviations or Unexplained Findings
Common examples include:
- Deviations that appear unrelated but actually impact interpretations
- Findings described in the text but missing from pathological summaries
- Outliers not explained
- Missing traceability for protocol amendments
Unexplained deviations can be interpreted as data reliability concerns, especially in GLP studies.
What to do:
Ensure deviations and unexpected observations are clearly documented, explained, and assessed for impact.
- Poorly Documented Methods, Assays, or Analytical Results
Regulators must be able to evaluate whether the study was conducted to acceptable standards.
Red flags include:
- Incomplete method descriptions
- Missing validation summaries
- Unclear bioanalytical acceptance criteria
- Missing or inconsistent sample handling procedures
Analytical details matter — especially when exposure margins are tight.
What to do:
Confirm all methods are properly described and that analytical results tie back to validated procedures.
- Lack of Clear Study Conclusions or Inadequate Integration
A strong study report should clearly explain:
- What was observed
- Why it matters
- How it translates to clinical use
Weak integrative summaries can lead to misinterpretation or additional regulatory questions.
Common examples:
- NOAEL listed but not scientifically justified
- Target organ toxicity mentioned without clear explanation
- Contradictions between text and histopathology tables
What to do:
Ensure the conclusion is a coherent, integrated interpretation — not just a narrative summary.
Why These Red Flags Matter
Regulators use study reports to evaluate:
- Data integrity
- Risk to human subjects
- Study adequacy for clinical progression
- Scientific consistency across the submission
Even a single unresolved red flag can trigger:
- Clinical hold questions
- Submission delays
- Additional preclinical work
- Loss of reviewer confidence
How Nikao Lifesciences Supports Report Quality
Our team provides comprehensive support, including:
- Draft and final report QC
- Cross-study data integration
- Pathology and toxicology interpretation
- Structuring defensible NOAEL and exposure margin justifications
- Ensuring GLP, ICH, and SEND alignment
- Vendor coordination and study oversight
Every report reviewed at Nikao Life Sciences is evaluated for accuracy, consistency, regulatory alignment, and completeness.
Need Support Reviewing a Study Report Before Submission?
Let Nikao Life Sciences ensure your study reports are defensible, compliant, and submission-ready.
📧 Email: info@nikaolifesci.com
🌐 Visit: www.nikaolifesciences.com
Science. Strategy. Global Execution.
